The abstract is read at the publisher; the summary is JClub's.
Semaglutide is linked to lower mortality on dialysis than dulaglutide or liraglutide in U.S. Medicare hemodialysis patients with diabetes, with sHR 0.82 (95% CI 0.70–0.97).
- Why it matters: Comparative effectiveness among diabetes patients on maintenance hemodialysis is uncertain, and head-to-head evidence is needed to guide glucagon-like peptide 1 selection.
- What they did: Using 2011–2022 U.S. Renal Data System and Medicare data, the study emulated a target trial of semaglutide versus dulaglutide or liraglutide with overlap weighting, Fine-Gray models for death/hospitalization, and a generalized estimating equation for repeated body weight.
- The result: After weighting (effective sample size 3,200), semaglutide also showed lower all-cause hospitalization risk (sHR 0.91, 95% CI 0.83–0.99) and greater 1-year body weight loss (-4.8% vs -3.4%); direct semaglutide–dulaglutide results were similar, while semaglutide–liraglutide showed no statistically significant benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.